Cary, NC — APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim...
Read MoreNews
APIE Therapeutics Provides Evidence that Activating
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
Read MoreAPIE Therapeutics Presented Preclinical Findings Supporting
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
Read MoreAPIE Therapeutics Augments Leadership Team with
APIE Therapeutics appoints Debra K. Bowes, MBEE and Seth Hetherington, M.D. to the positions of chief business officer and chief medical officer, respectively.
Read MoreAPIE Therapeutics Prepares to Advance Pipeline
APIE Therapeutics appoints Robert Willette, Ph.D. to the newly created role of chief scientific officer.
Read MoreAPIE Therapeutics Expands Board of Directors
Diane K. Jorkasky, M.D. FACP brings over three decades of experience in all stages of clinical development to the APIE Therapeutics board.
Read MoreRTI International Licenses Portfolio of Compounds
The agreement advances APIE Therapeutics’ pursuit of a treatment for idiopathic pulmonary fibrosis, a rare lung disease
Read More